261 related articles for article (PubMed ID: 30980785)
1. Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study.
Bajis S; Grebely J; Cooper L; Smith J; Owen G; Chudleigh A; Hajarizadeh B; Martinello M; Adey S; Read P; Gilliver R; Applegate T; Treloar C; Maher L; Dore GJ
J Viral Hepat; 2019 Aug; 26(8):969-979. PubMed ID: 30980785
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
[TBL] [Abstract][Full Text] [Related]
3. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
[TBL] [Abstract][Full Text] [Related]
4. Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department.
Hutton J; Doyle J; Zordan R; Weiland T; Cocco A; Howell J; Iser S; Snell J; Fry S; New K; Sloane R; Jarman M; Phan D; Tran S; Pedrana A; Williams B; Johnson J; Glasgow S; Thompson A
Int J Drug Policy; 2019 Oct; 72():84-90. PubMed ID: 31351752
[TBL] [Abstract][Full Text] [Related]
5. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
[TBL] [Abstract][Full Text] [Related]
6. Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence.
Sulkowski M; Luetkemeyer AF; Wyles DL; Martorell C; Muir A; Weisberg I; Gordon SC; McLain R; Huhn G
Aliment Pharmacol Ther; 2020 Jun; 51(12):1384-1396. PubMed ID: 32352586
[TBL] [Abstract][Full Text] [Related]
7. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
[TBL] [Abstract][Full Text] [Related]
8. A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C.
Ramsay J; Marsh J; Pedrana A; Andric N; Norman R; Cheng W; Webb S; Zeps N; Bellgard M; Graves T; Hellard M; Snelling T
BMC Infect Dis; 2020 Oct; 20(1):802. PubMed ID: 33121439
[TBL] [Abstract][Full Text] [Related]
9. Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia.
Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J;
Int J Drug Policy; 2018 Nov; 61():23-30. PubMed ID: 30388566
[TBL] [Abstract][Full Text] [Related]
10. Shelter-Based Integrated Model Is Effective in Scaling Up Hepatitis C Testing and Treatment in Persons Experiencing Homelessness.
Khalili M; Powell J; Park HH; Bush D; Naugle J; Ricco M; Magee C; Braimoh G; Zevin B; Fokuo JK; Masson CL
Hepatol Commun; 2022 Jan; 6(1):50-64. PubMed ID: 34628726
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus care cascade in persons experiencing homelessness in the United States in the era of direct-acting antiviral agents: A scoping review.
Del Rosario A; Eldredge JD; Doorley S; Mishra SI; Kesler D; Page K
J Viral Hepat; 2021 Nov; 28(11):1506-1514. PubMed ID: 34314081
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C Virus Reinfection in a Real-World Cohort of Homeless-Experienced Individuals in Boston.
Beiser ME; Shaw LC; Shores SK; Carson JM; Hajarizadeh B
Clin Infect Dis; 2023 Jul; 77(1):46-55. PubMed ID: 36869823
[TBL] [Abstract][Full Text] [Related]
13. Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy.
Wong GL; Chan HL; Loo CK; Hui YT; Fung JY; Cheung D; Chung C; Chim AM; Wong VW;
J Gastroenterol Hepatol; 2019 Sep; 34(9):1641-1647. PubMed ID: 30707777
[TBL] [Abstract][Full Text] [Related]
14. Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility.
MacIsaac MB; Whitton B; Anderson J; Cogger S; Vella-Horne D; Penn M; Weeks A; Elmore K; Pemberton D; Winter RJ; Papaluca T; Howell J; Hellard M; Stoové M; Wilson D; Pedrana A; Doyle JS; Clark N; Holmes JA; Thompson AJ
Int J Drug Policy; 2024 Mar; 125():104317. PubMed ID: 38281385
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C care cascade before and during the direct-acting antiviral eras in New South Wales, Australia: A population-based linkage study.
Yousafzai MT; Alavi M; Valerio H; Hajarizadeh B; Grebely J; Dore GJ
J Viral Hepat; 2023 Mar; 30(3):250-261. PubMed ID: 36537024
[TBL] [Abstract][Full Text] [Related]
16. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J;
Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated with Sustained Virologic Response to Hepatitis C Treatment in a Homeless-Experienced Cohort in Boston, 2014-2020.
Beiser ME; Shaw LC; Wilson GA; Muse KO; Shores SK; Baggett TP
J Gen Intern Med; 2023 Mar; 38(4):865-872. PubMed ID: 36127534
[TBL] [Abstract][Full Text] [Related]
18. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington.
Corcorran MA; Tsui JI; Scott JD; Dombrowski JC; Glick SN
Drug Alcohol Depend; 2021 Mar; 220():108525. PubMed ID: 33461152
[TBL] [Abstract][Full Text] [Related]
19. Community-Based Assessment and Treatment of Hepatitis C Virus-Related Liver Disease, Injecting Drug and Alcohol Use Amongst People Who Are Homeless: A Systematic Review and Meta-Analysis.
Hashim A; Macken L; Jones A; McGeer M; Aithal G; Verma S
Int J Drug Policy; 2021 Oct; 96():103342. PubMed ID: 34210551
[TBL] [Abstract][Full Text] [Related]
20. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.
Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J
Clin Infect Dis; 2021 Jul; 73(1):e69-e78. PubMed ID: 32421194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]